Tissue and Liquid Biopsies in Metastatic Urothelial Cancer
A discussion on current prognostic and predictive testing assays used to detect FGFR mutations in patients with metastatic urothelial cancer (mUC).
Read More
THIO Plus Cemiplimab Displays Efficacy in Checkpoint Inhibitor–Resistant NSCLC
CD47 Levels Are Prognostic of Response to Magrolimab Plus Docetaxel in Metastatic NSCLC
Frontline Vibostolimab/Pembrolizumab Plus Chemo Meets Futility Threshold in ES-SCLC
PD-L1, KIM-1 Expression Are Predictive of Outcomes With Adjuvant Nivolumab Alone, Plus Ipilimumab in ccRCC